SCHEMBL20567334

SCHEMBL20567334

CCOc1cc(Oc2ccc(N3C(=O)N[C@H](CC)C3=O)cn2)ccc1C

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.39
LMNA P02545 2/20 0.35
OXTR P30559 3/20 0.35
ALDH1A1 P00352 5/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TP53 P04637 1/20 0.33
HRH3 Q9Y5N1 5/20 0.33
AVPR1A P37288 2/20 0.33
MAPK1 P28482 1/20 0.33
HRH1 P35367 1/20 0.32
MMP13 P45452 1/20 0.32
KDM4E B2RXH2 1/20 0.32
POLB P06746 1/20 0.32
USP2 O75604 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30939542 0.92 DRD1 (0.38) NPSR1OXTRALDH1A1HRH3HRH1
SCHEMBL29381475 0.92 DRD1 (0.38) NPSR1OXTRALDH1A1HRH3HRH1
SCHEMBL20599031 0.92 DRD1 (0.38) NPSR1OXTRALDH1A1HRH3HRH1
SCHEMBL1982377 0.92 DRD1 (0.38) NPSR1OXTRALDH1A1HRH3HRH1
SCHEMBL1980580 0.92 DRD1 (0.38) NPSR1OXTRALDH1A1HRH3HRH1
SCHEMBL30939529 0.88 POLB (0.34) NPSR1MAPK1MMP13POLB
SCHEMBL1978383 0.88 POLB (0.34) NPSR1MAPK1MMP13POLB
SCHEMBL30939590 0.88 NPSR1 (0.38) NPSR1LMNAALDH1A1MEN1KMT2A
SCHEMBL1979317 0.88 NPSR1 (0.38) NPSR1LMNAALDH1A1MEN1KMT2A
SCHEMBL22026246 0.87 NPSR1 (0.45) NPSR1LMNAALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 US disclosed
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 NPSR1 561/4885LMNA 2187/4885OXTR 890/4885
US-10632118-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 NPSR1 561/4885LMNA 2187/4885OXTR 890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.